ALVESCO Drug Patent Profile
✉ Email this page to a colleague
When do Alvesco patents expire, and when can generic versions of Alvesco launch?
Alvesco is a drug marketed by Covis and is included in one NDA. There is one patent protecting this drug.
This drug has fourteen patent family members in twelve countries.
The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ciclesonide profile page.
DrugPatentWatch® Generic Entry Outlook for Alvesco
Alvesco was eligible for patent challenges on October 20, 2010.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 1, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALVESCO?
- What are the global sales for ALVESCO?
- What is Average Wholesale Price for ALVESCO?
Summary for ALVESCO
International Patents: | 14 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 64 |
Clinical Trials: | 10 |
Drug Prices: | Drug price information for ALVESCO |
What excipients (inactive ingredients) are in ALVESCO? | ALVESCO excipients list |
DailyMed Link: | ALVESCO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ALVESCO
Generic Entry Date for ALVESCO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
AEROSOL, METERED;INHALATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ALVESCO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2/Phase 3 |
Covis Pharma S.à.r.l. | Phase 3 |
Ola Blennow, MD, PhD | Phase 2 |
US Patents and Regulatory Information for ALVESCO
ALVESCO is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ALVESCO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ALVESCO
Use of ciclesonide for the treatment of respiratory diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-002 | Jan 10, 2008 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALVESCO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ALVESCO
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim Vetmedica GmbH | Aservo EquiHaler | ciclesonide | EMEA/V/C/004991 For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction – (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)). |
Authorised | no | no | no | 2020-01-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ALVESCO
See the table below for patents covering ALVESCO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Slovenia | 0983058 | ⤷ Sign Up | |
Spain | 2077971 | ⤷ Sign Up | |
Portugal | 98897 | PROCESSO PARA A PREPARACAO DE NOVOS ESTERES DE PREGNA-1,4-DIENO-3,20-DIONA-16-17-ACETAL-21 E SUAS COMPOSICOES APLICAVEIS NO TRATAMENTO DE CONDICOES INFLAMATORIAS | ⤷ Sign Up |
Japan | 3260752 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ALVESCO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0983058 | PA2005006,C0983058 | Lithuania | ⤷ Sign Up | PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321 |
0983058 | PA2005006 | Lithuania | ⤷ Sign Up | PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321 |
0983058 | CA 2005 00036 | Denmark | ⤷ Sign Up | |
0983058 | SPC022/2005 | Ireland | ⤷ Sign Up | SPC022/2005, 20060612, EXPIRES: 20190415 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |